Weekly metabolic injections do not replace bariatric surgery—they rescue it from failure.
Instead of rendering surgical intervention obsolete, GLP-1 therapies are emerging as crucial post-operative complements that salvage suboptimal surgical outcomes and reverse weight regain.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Clinicians and bariatric surgeons are actively positioning GLP-1s as complementary post-operative tools to combat weight regain rather than simple surgical replacements.
The trial establishes that GLP-1 therapies function as crucial post-surgical supports that rescue bariatric interventions from early failure.
The first RCT of GLP-1s after failed surgery positions the drug as the salvage complement to the scalpel, not its replacement.